Alkem Laboratories has introduced semaglutide injection in India, targeting type-2 diabetes mellitus and chronic weight management. The therapy is priced at an accessible ₹450 per week, aiming to enhance healthcare outcomes for patients.
Alkem’s semaglutide is available under the brand names ‘Semasize’, ‘Obesema’, and ‘Hepaglide’. The pre-filled disposable injection pen is priced at ₹1,800 for a month’s dosage, translating to a weekly cost of ₹450. Additionally, Alkem offers a reusable injection pen for higher maintenance doses, allowing patients to replace only the medication cartridge, thereby reducing costs and improving adherence to treatment.
The company has received approval from the Drug Controller General of India (DCGI) for manufacturing and marketing semaglutide, following a review of Phase 3 clinical trials conducted in India. Semaglutide is a prescription product and should be administered under medical supervision.
Dr. Vikas Gupta, CEO of Alkem, emphasised the importance of making therapeutic advancements accessible. He stated, ‘With the launch of our indigenously-developed semaglutide, we are bringing a high-quality and affordable option to market, empowering healthcare practitioners to offer this therapy to more deserving patients.’
Alkem Laboratories, a leading Indian pharmaceutical company, has a strong distribution network and aims to make this product accessible to a larger population, contributing to improved healthcare outcomes.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).